BR112018005837A2 - anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica - Google Patents

anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica

Info

Publication number
BR112018005837A2
BR112018005837A2 BR112018005837A BR112018005837A BR112018005837A2 BR 112018005837 A2 BR112018005837 A2 BR 112018005837A2 BR 112018005837 A BR112018005837 A BR 112018005837A BR 112018005837 A BR112018005837 A BR 112018005837A BR 112018005837 A2 BR112018005837 A2 BR 112018005837A2
Authority
BR
Brazil
Prior art keywords
antibody
nucleic acid
vector
mesothelin
pharmaceutical composition
Prior art date
Application number
BR112018005837A
Other languages
English (en)
Inventor
Kim Dong-Sik
Jung Song Eun
Lee Mijung
Lee Eun-Hee
Oh Miyoung
Chan Park Jae
Kim Kisu
Kim Sujeong
Lim Hyung-Kwon
Lee Kyuhyun
Won Jongwha
Choi Soongyu
Seoub Park Young
Original Assignee
Mogam Institute For Biomedical Research
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Institute For Biomedical Research, Green Cross Corporation filed Critical Mogam Institute For Biomedical Research
Publication of BR112018005837A2 publication Critical patent/BR112018005837A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica se refere a um anticorpo especificamente ligado a mesotelina (msln), um ácido nucleico que codifica o anticorpo, um vetor e uma célula hospedeira incluindo o ácido nucleico, um método para preparar o anticorpo e uma composição farmacêutica para tratar câncer ou tumor incluindo o anticorpo como um ingrediente ativo. o anticorpo especificamente ligado à mesotelina, de acordo com a presente invenção, tem alta afinidade e especificidade a um antígeno, de tal forma que é possível desenvolver um anticorpo efetivamente utilizável para o tratamento ou diagnóstico de câncer ou doenças tumorais.
BR112018005837A 2015-09-24 2016-09-23 anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica BR112018005837A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150135755A KR101782487B1 (ko) 2015-09-24 2015-09-24 신규 항-메소텔린 항체 및 이를 포함하는 조성물
PCT/KR2016/010604 WO2017052241A1 (en) 2015-09-24 2016-09-23 Novel anti-mesothelin antibody and composition comprising the same

Publications (1)

Publication Number Publication Date
BR112018005837A2 true BR112018005837A2 (pt) 2018-10-09

Family

ID=58386441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005837A BR112018005837A2 (pt) 2015-09-24 2016-09-23 anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica

Country Status (13)

Country Link
US (1) US10851175B2 (pt)
EP (1) EP3353213B1 (pt)
JP (1) JP6738893B2 (pt)
KR (1) KR101782487B1 (pt)
CN (3) CN108350084B (pt)
AU (1) AU2016328204B2 (pt)
BR (1) BR112018005837A2 (pt)
CA (1) CA2999237C (pt)
EA (1) EA038654B1 (pt)
ES (1) ES2857500T3 (pt)
IL (1) IL258215B (pt)
MX (1) MX2018003470A (pt)
WO (1) WO2017052241A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3472207T (pt) 2016-06-20 2021-03-31 F Star Delta Ltd Moléculas ligantes que se ligam a pd-l1 e lag-3
RU2018142573A (ru) 2016-06-20 2020-07-21 Ф-Стар Бета Лимитед Партнеры по связыванию lag-3
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2019005208A1 (en) * 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
EP3728316A1 (en) 2017-12-19 2020-10-28 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
KR102070016B1 (ko) * 2019-01-21 2020-01-29 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
WO2020204305A1 (ko) * 2019-03-29 2020-10-08 주식회사 녹십자 항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도
KR102216225B1 (ko) * 2019-06-27 2021-02-17 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
KR102309543B1 (ko) * 2020-08-04 2021-10-07 주식회사 셀렌진 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체
US11795215B2 (en) 2020-08-04 2023-10-24 Cellengene Inc Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin
KR102507337B1 (ko) * 2021-05-26 2023-03-08 주식회사 셀렌진 항 메소텔린 scFv를 포함하는 키메릭 항원 수용체 및 이의 용도
KR20230005001A (ko) * 2021-06-30 2023-01-09 (주)이노베이션바이오 메소텔린 특이적 항체 및 이의 용도
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
CN114423789B (zh) * 2021-12-24 2022-09-30 浙江时迈药业有限公司 针对间皮素的抗体及其用途
KR20240043161A (ko) * 2022-09-23 2024-04-03 국민대학교산학협력단 Grp94에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 및 약물을 포함하는 항체 약물 컨쥬게이트
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2386367T3 (es) 2005-03-10 2012-08-17 Morphotek, Inc. Anticuerpos anti-mesotelina
KR101554848B1 (ko) * 2007-10-01 2015-09-21 브리스톨-마이어스 스큅 컴퍼니 메소텔린에 결합하는 인간 항체 및 이의 용도
US20100222289A1 (en) 2007-10-22 2010-09-02 Cfs Research Llc Methods for diagnosis and treatment of chronic fatigue syndrome
CA2706529C (en) * 2007-11-26 2016-10-25 Bayer Schering Pharma Aktiengesellschaft Anti-mesothelin antibodies and uses therefor
EP2257572A1 (en) * 2008-03-27 2010-12-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Human anti-mesothelin monoclonal antibodies
PH12018500046A1 (en) * 2010-12-20 2019-04-08 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
AU2013306076B2 (en) * 2012-08-21 2018-01-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
KR20150029457A (ko) * 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도

Also Published As

Publication number Publication date
CN113603785B (zh) 2024-01-05
IL258215A (en) 2018-05-31
CA2999237A1 (en) 2017-03-30
WO2017052241A1 (en) 2017-03-30
CN113603785A (zh) 2021-11-05
AU2016328204B2 (en) 2019-03-21
KR20170036503A (ko) 2017-04-03
EA038654B1 (ru) 2021-09-29
MX2018003470A (es) 2019-10-30
US10851175B2 (en) 2020-12-01
EP3353213A1 (en) 2018-08-01
CN108350084A (zh) 2018-07-31
KR101782487B1 (ko) 2017-09-27
IL258215B (en) 2022-07-01
JP2018532401A (ja) 2018-11-08
CN118085094A (zh) 2024-05-28
AU2016328204A1 (en) 2018-04-19
CN108350084B (zh) 2021-09-10
EA201890796A1 (ru) 2018-10-31
JP6738893B2 (ja) 2020-08-12
ES2857500T3 (es) 2021-09-29
EP3353213A4 (en) 2019-05-29
EP3353213B1 (en) 2020-12-02
US20180346588A1 (en) 2018-12-06
CA2999237C (en) 2021-07-06

Similar Documents

Publication Publication Date Title
BR112018005837A2 (pt) anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
PH12018500642A1 (en) Anti-garp antibody
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112017009552A2 (pt) métodos para alvejar o controle transcricional em regiões de super-realçador
BR112018011969A2 (pt) compostos heteroaromáticos como inibidores de btk
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
BR102014029197A8 (pt) conjugado, seu processo de obtenção, uso, composição farmacêutica, ácido nucléico, vetor e célula hospedeira.
ZA201902384B (en) Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
BR112018008840A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]